Alternatives to CRISPR Therapeutics

Scalable, one-time curative in-vivo gene editing therapies.

Biotechnology company leveraging ultracompact CRISPR systems for gene editing therapies and diagnostics.

A clinical-stage biotechnology company developing in vivo gene editing therapies.

Developing disease-responsive advanced therapies through programmable gene control technology.

Global supplier of life science research tools, including antibodies, reagents, and assays.

A biotechnology company developing precision genetic medicines through base editing technology to treat a broad range of diseases.

Developing magnetic cell delivery platform for advanced therapies.

Arrakis Bio is developing novel therapeutics for cancer and other diseases using a proprietary gene editing platform.

Developing genetic medicines and cell therapies for severe diseases using proprietary CRISPR OMNI technology.

A clinical-stage biotechnology company developing transformative genome editing medicines for serious diseases.

A clinical-stage genome editing company developing novel therapies using CRISPR/Cas9 technology for severe diseases.

Omega Therapeutics is developing a new class of programmable medicines called Epigenomic Controllers.

Gene therapy company developing transformative treatments for severe genetic diseases.

Developing polymer-based nanoparticles for targeted gene therapy delivery.

Develops advanced gene editing and cell therapy solutions for rare genetic diseases.

Biotechnology company developing cell and gene therapies for serious diseases.

VI Therapeutics is developing novel therapies for rare genetic diseases.

Developing gene editing therapies for rare genetic diseases.

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.